IMA ImageneBio Inc
USHealthcareAs of 2026-08-24
Why IMA matters now
ImageneBio Inc (IMA) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.59 with +1.45% on the session and $63.1M in market capitalization; recent performance reads 1-month +14.29% and YTD -13.04%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.6M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -77.0%.
The latest indexable market news headline is "ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $1.33; recent insider activity includes Bonita David P filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.55
P/S
0.00
EV/EBITDA
0.00
DCF Value
$4.99
FCF Yield
-77.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.2%
ROA
-33.0%
ROIC
-42.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.6M | $-0.95 |
| Q4 2025 | $0.00 | $-6.9M | $-0.62 |
| FY 2025 | $800.0K | $-45.3M | $-10.76 |
| Q3 2025 | $0.00 | $-24.8M | $-3.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$1.33
Target (Median)
$1.33
Target Range
$1.33 - $1.33
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.72
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.